{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"19"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"38"}],"units":"Participants"}],"description":"PFS: Number of participants, per treatment arm with progression free survival at time of analysis. Survival time will be measured from the date of transplant to the date of progression, death or the last follow-up, whichever comes first. Progressive Disease (PD): Increase of ≥ 25% from lowest response value in any one or more of the following: Serum M-component and/or; Urine M-component and/or; Only in patients without measurable serum and urine M-protein levels; the difference between involved and uninvolved FLC levels. The absolute increase must be \\> 10 mg/dL; Bone marrow plasma cell percentage; absolute percentage ≥ 10%; Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia that can be attributed solely to the plasma cell proliferative disorder.","groups":[{"description":"Allogeneic Stem Cell Transplant: Fludarabine+Melphalan+Bortezomib followed by Allogeneic Rescue.","id":"OG000","title":"A: Allogeneic Stem Cell Transplant"},{"description":"Autologous Stem Cell Transplant: Melphalan+Bortezomib followed by Autologous Rescue.","id":"OG001","title":"B: Autologous Stem Cell Transplant"},{"description":"Group B Expansion on Bortezomib Maintenance: Autologous Only.","id":"OG002","title":"BE: Group B Expansion"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants evaluable at time of analysis","reportingStatus":"POSTED","timeFrame":"End of 2 year, post transplant follow-up","title":"Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Participants"}